Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
GlaxoSmithKline plc
Index- P/E27.71 EPS (ttm)1.70 Insider Own- Shs Outstand2.42B Perf Week-1.94%
Market Cap114.02B Forward P/E16.80 EPS next Y2.80 Insider Trans- Shs Float2.39B Perf Month-2.30%
Income4.12B PEG- EPS next Q- Inst Own10.10% Short Float0.21% Perf Quarter9.37%
Sales34.41B P/S3.31 EPS this Y-48.60% Inst Trans0.10% Short Ratio1.47 Perf Half Y12.99%
Book/sh2.61 P/B18.05 EPS next Y2.67% ROA6.90% Target Price46.36 Perf Year-5.40%
Cash/sh2.68 P/C17.59 EPS next 5Y- ROE50.00% 52W Range40.65 - 53.55 Perf YTD11.83%
Dividend2.78 P/FCF- EPS past 5Y-12.10% ROI15.00% 52W High-12.05% Beta0.65
Dividend %5.90% Quick Ratio0.80 Sales past 5Y-4.10% Gross Margin69.40% 52W Low15.87% ATR0.60
Employees98702 Current Ratio1.10 Sales Q/Q-10.40% Oper. Margin22.30% RSI (14)46.91 Volatility0.83% 1.05%
OptionableYes Debt/Eq4.41 EPS Q/Q-57.40% Profit Margin11.80% Rel Volume0.76 Prev Close47.29
ShortableYes LT Debt/Eq3.72 EarningsMay 06 Payout141.60% Avg Volume3.50M Price47.10
Recom2.80 SMA20-0.76% SMA50-0.05% SMA2003.09% Volume2,656,427 Change-0.40%
Apr-15-15Initiated Societe Generale Sell
Feb-19-15Reiterated Argus Buy $55 → $52
Aug-08-14Reiterated Argus Buy $65 → $55
Apr-23-14Upgrade Argus Hold → Buy
May-28-13Upgrade Deutsche Bank Hold → Buy
Jan-11-11Upgrade Jefferies Hold → Buy
Jun-02-10Upgrade Jefferies Hold → Buy
Feb-16-10Upgrade JP Morgan Underweight → Neutral $26
Jan-13-10Downgrade Credit Suisse Outperform → Underperform
Nov-24-09Initiated Leerink Swann Mkt Perform
Nov-16-09Initiated Deutsche Securities Hold
Nov-12-09Initiated Barclays Capital Equal Weight
Oct-23-09Downgrade Jefferies & Co Buy → Hold
Mar-17-09Initiated Credit Suisse Outperform
Jan-26-09Initiated Jefferies & Co Buy
Nov-14-08Downgrade UBS Buy → Neutral
Apr-18-08Downgrade JP Morgan Neutral → Underweight
Feb-11-08Upgrade UBS Neutral → Buy
Feb-01-08Upgrade HSBC Securities Underweight → Neutral
Oct-24-07Initiated Bernstein Mkt Perform
Apr-20-15 03:02PM  BioMed Realty, L.P. -- Moody's upgrades BioMed's senior unsecured ratings to Baa2; outlook is stable at Moody's
Apr-17-15 07:44PM  Veeva's Latest Solution to Ease Medical Product Rollouts - Analyst Blog
06:40PM  Pfizer Wins First Trial Over Zoloft Birth-Defect Claims
03:26PM  Glaxo recalls flu vaccine due to potency problem
02:35PM  Why Raleigh-Durham International Airport needs a new GlaxoSmithKline at
02:27PM  Pfizer Jury Told Zoloft Risks Known But Hidden From Patients at Bloomberg
10:09AM  Maverick Capital Increases Stake in Novartis
08:51AM  [video]Buy These 4 High-Yield Dividend Stocks to Take Advantage of the Health Care Boom at TheStreet
Apr-16-15 05:05PM  Glaxo Downgraded to Strong Sell, Delete from Your Portfolio - Analyst Blog
12:48PM  Exclusive: GlaxoSmithKline shutting Moon office; 274 employees affected at
11:41AM  How Marketing And Media Muddled The Truth About The Heart Drug Vytorin at Forbes
Apr-15-15 05:00PM  Merck, NewLink Ebola Vaccine Enters Third Phase III Study - Analyst Blog
Apr-14-15 02:45PM  GSK considers changes to sales force compensation plans at
Apr-13-15 11:34AM  Glaxo to Change its Compensation Program for U.S. Sales Reps at The Wall Street Journal
11:10AM  Tekmira Up on Ebola Candidate Update from the FDA - Analyst Blog
09:47AM  Should The FDA Require CV Outcome Studies For Diabetes Drugs Before Approval? at Forbes
Apr-08-15 06:51AM  Shells BG Buy Trumps GlaxoSmithKline as Biggest U.K.-Only Deal at Bloomberg
Apr-07-15 02:31PM  3 Hale & Hearty Stocks for World Health Day - Analyst Blog
Apr-06-15 08:01AM  Workplace wellness has a long way to go at Financial Times
Apr-03-15 04:20PM  Q&A: How GSK/Salix layoffs will impact the Triangle at
07:25AM  GlaxoSmithKline to move 150 Cambridge vaccine research jobs out of state at
03:11AM  Pfizer halts China vaccine sales after import license not renewed at Financial Times
Apr-02-15 01:45PM  GlaxoSmithKline to open global R&D center in Rockville at
11:39AM  GSK to establish global vaccines R&D centre in the US at noodls
Apr-01-15 09:50PM  Pfizer Says Ceasing Vaccine Commercial Operations in China at Bloomberg
02:05PM  EWU Fell 1.69% despite Positive Economic Growth in the UK
02:05PM  Why Is Pfizers Revenue Stream Declining?
09:55AM  From The Pantry to GlaxoSmithKline: North Carolina layoffs inch up in March at
07:20AM  Has Lack Of Revenue Growth Stunted Pharma R&D Investments? at Forbes
05:02AM  Shares Of Chinese Sports-Lottery Firm Down Due To Corruption Rumors at Forbes
Mar-31-15 07:06PM  Ascend Capital Opens New Position in Gilead Sciences
04:50PM  The Future of Big Pharma Stocks at Investopedia
02:55PM  Personalized medicine a factor in Quintiles-Quest JV at
10:17AM  Millions To Be Made On...Generic Drugs? at Forbes
Mar-30-15 06:36PM  J&J, Glaxo settle U.S. lawsuit over allergy ads at Fortune
06:07PM  J&J, Glaxo settle U.S. lawsuit over allergy ads Reuters
02:06PM  Biopharmaceutical Business: Why Its Important for Pfizer
09:55AM  Durham's acne drug developer raises $50M, partly from Jim Goodnight at
Mar-29-15 03:19PM  Dragons' Den, Shark Tank And Edison Nation: Is Reality TV Good for Business? at Forbes
12:09PM  Britain to offer all infants meningitis B vaccine
11:00AM  Medics welcome GSK deal to provide meningitis B vaccine at Financial Times
Mar-27-15 06:40PM  BioMarin Pharma Hits All-Time High at Investor's Business Daily
07:18AM  China pulls back tax breaks for foreign companies at
Mar-26-15 07:08PM  Two Experimental Ebola Vaccines Show Promise at The Wall Street Journal
05:39PM  Two experimental Ebola vaccines pass safety test in African trial Reuters
11:18AM  Actavis takes 'specialty pharma' route to health at Financial Times
04:01AM  GSK receives approval for Encruse® Ellipta® in Japan for the treatment of COPD at noodls
Mar-25-15 05:20PM  Ligand Pharmaceuticals: Biotech's Jack Of All Trades at Investor's Business Daily
01:20PM  Veeva (VEEV) OpenKey: A Key to Customer Data Referencing - Analyst Blog
10:59AM  From Snitch Pill to Xbox Sensors, Novartis Goes Digital
Mar-24-15 07:00PM  From Pills That Snitch to Xbox Sensors, Drugmaker Goes High Tech
02:26PM  Stocks to Cure What Ails on World TB Day - Analyst Blog
12:47PM  Agenus Boosted by Big Pharma Deals at
11:19AM  GSKs 2015 Discovery Fast Track Challenge seeks early drug discovery partnerships with academics in Europe, Canada and US at noodls
09:00AM  TG Therapeutics Is A Best Idea at Forbes
Mar-23-15 02:14PM  Biogen downgrade, Pfizer rises
01:52PM  When school is out, science is in! GSK Science in the Summer goes national PR Newswire
Mar-21-15 09:41AM  GlaxoSmithKline Wants to Conclude U.K. Talks Over Vaccine Price at Bloomberg
Mar-20-15 05:41PM  Seven signs you are clueless about income inequality at Fortune
02:00PM  Theravance/Glaxo's Breo Ellipta Gets Mixed FDA Panel View - Analyst Blog
Mar-19-15 08:07PM  UK businesses lobby for better cycling infrastructure at Financial Times
07:11PM  U.S. Panel Backs Glaxos Breo for Asthma in Adults, Not Kids at Bloomberg
06:12PM  FDA panel backs Glaxo inhaler for adults, not adolescents
06:06PM  GSK and Theravance announce outcome of US FDA Advisory Committee on BREO® ELLIPTA® in asthma at noodls
04:56PM  FDA panel backs Glaxo asthma drug for adults, not adolescents Reuters
04:20PM  AstraZeneca Up on Positive Late-Stage Lung Disease Results - Analyst Blog
04:10PM  Pfizer Announces Publication of CAPiTA Data on Prevenar 13 - Analyst Blog
Mar-18-15 02:20PM  Novartis' Jakavi Gets EC Approval for Polycythemia Vera - Analyst Blog
01:05PM  Declining oil prices benefit Europe, says Draghi
12:30PM  Veeva Picked as CRM Partner by GlaxoSmithKline, Stock Up - Analyst Blog
09:34AM  Veeva Systems Inc (VEEV): Criterion Capital Among Top Winners as Stock Goes Up; Check Out Funds Other Top Picks at Insider Monkey
08:30AM  A Decade Old Drug Launch In China With Important Insights Today at Forbes
Mar-17-15 05:20PM  MGM and Black Diamond are big market movers
01:12PM  China FCPA Due Diligence Hits New Levels Amid M&A Spree at Forbes
10:40AM  Emergent BioSolutions Inks Deals for Its Ebola Vaccine - Analyst Blog
09:32AM  FDA staff finds no new safety problems with Glaxo's asthma drug Reuters
04:19AM  GSK becomes partner in new global fund to accelerate dementia research at noodls
04:19AM  GSK announces intention to sell part of its holding in Aspen Pharmacare Holdings Ltd at noodls
04:00AM  Dementia drug research aided by $100 mln venture capital fund
Mar-16-15 08:16PM  Dementia research boosted by $100m venture capital fund at Financial Times
04:02PM  A Case for Foreign Dividend Stocks at
12:06PM  France, Ireland, and Spain Report Negative Inflation
08:11AM  Ebola booster vaccine trial to combine GSK, Emergent Bio shots
Mar-13-15 11:11PM  Preview at
10:48PM  Next Week at
06:37PM  This Top Stock Is Ripe For A Buyout Or Acquisition at Investor's Business Daily
11:30AM  McNeil sues GlaxoSmithKline over allergy medicine ad at
11:19AM  Par Pharmaceutical Files To Return To Stock Market at Investor's Business Daily
10:10AM  ChemoCentryx's Q4 Loss Meet Estimates, Pipeline in Focus - Analyst Blog
06:37AM  GSK completes partial sale of Aspen Pharmacare Holdings Ltd shares at noodls
06:31AM  GSK completes partial sale of Aspen Pharmacare Holdings Ltd shares (1) at noodls
06:25AM  GSK transaction at noodls
04:14AM  GlaxoSmithKline Offloads Half its Aspen Shares for $851 Million at Bloomberg
03:24AM  GSK to sell Aspen stake for £574m at Financial Times
Mar-12-15 07:05PM  UK Joins the Rest of Europe in the Industrial Slowdown
07:05PM  Exploring Johnson & Johnsons Pharmaceuticals Segment
05:26PM  Big pharma's bet on tech
12:57PM  GSK transaction launch at noodls
Mar-11-15 09:48AM  GSK announces major new commitment to Asia at noodls
09:00AM  Theravance Biopharma Q4 Loss Widens Y/Y, Revenues Up - Analyst Blog
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company's wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company's nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLC10% OwnerMar 02Buy18.0692,6741,673,69231,673,853Mar 02 03:45 PM
GLAXOSMITHKLINE PLC10% OwnerAug 11Buy22.66172,6513,912,27230,748,723Aug 11 04:55 PM
GLAXOSMITHKLINE PLC10% OwnerMay 09Buy26.89317,7708,544,83530,576,072May 13 04:43 PM